FirstCash Holdings heads into its October 22 earnings date with short sellers adding exposure at a steady clip while options traders make the starkest bullish bet in months.
The options market is telling the clearest story this week. Positioning has rarely been this one-sided — the put/call ratio has collapsed to 0.18, nearly 1.7 standard deviations below its 20-day average of 0.28 and close to the 52-week low of 0.10. That means call volume is swamping puts by more than five to one, a reading consistent with traders pricing in a strong Q3 print rather than hedging against disappointment. The contrast with the mid-September period is stark: the PCR was running near 0.34 for most of that stretch before dropping sharply the week of September 21.
Short interest tells a different, more cautious story beneath the surface. Bears have added exposure steadily across the past month, with short interest climbing 8.6% to 5.6% of the free float — roughly 2.48 million shares. The weekly pace has picked up too, with a 6.1% increase in the most recent five days. That is a moderate but deliberate build, not a panic short. The borrow market does not signal any stress: availability remains ample at roughly 397% of short interest, meaning almost four shares sit available for every one already borrowed. Cost to borrow has moved upward — rising 21% over the past week to 0.55% — but that level remains well within the "low" classification and poses no friction for new short positions. The short score has edged higher each day this week, reaching 52.8 on September 24, but remains firmly in neutral territory. Positioning here looks cautious rather than crowded.
The Street is broadly constructive. The most recent action came in August, when Loop Capital's Anthony Chukumba upgraded the stock to Buy with a $255 target — the highest on the board. TD Cowen and Canaccord Genuity have both ratcheted targets higher through 2026, all maintaining Buy ratings, with consensus clustered in the $240-$255 range against a current price of $217.45. That implies roughly 10-17% upside from here according to covering analysts. Valuation is not stretched: the trailing PE of 17.3x has drifted lower over the past month, while the EV/EBITDA multiple of 12.1x has held relatively steady. Factor scores flag dividend strength at the 99th percentile — though the dividend history on file is stale, dating to 2022 — while the short score rank sits at just the 18th percentile, consistent with the non-aggressive short positioning the data shows.
Institutional holders have been incrementally adding. Capital Research lifted its stake by more than 620,000 shares in the most recent reported period, the single largest net addition in the top-holder register. T. Rowe Price added over 311,000 shares. BlackRock holds 11.6% of shares outstanding and has also grown its position. On the insider side, the 90-day picture shows net selling of approximately $4.6 million across 20,900 shares, though the majority of that activity — sales by the CFO, COO, and AFF President — was executed under pre-arranged 10b5-1 plans, which reduces the signal value considerably. A September 3 discretionary sale by Director James Graves of 3,750 shares at $221.20 is the only non-plan transaction and, at roughly $830,000, does not represent an unusual level for a director liquidation.
History offers a relevant flag for the October print. The two most recent earnings events produced divergent outcomes: a 6.5% one-day gain after the April 23 Q1 report, followed by a sharp 6.6% one-day decline after the July 23 Q2 report. The five-day window after Q2 extended the loss to -3.3%, while the five-day window after Q1 extended the gain to +6.1%. The stock has a demonstrated tendency for large moves on results day, which the current extreme in call-side options positioning may be pricing — or mispricing. Closest peer EZPW gained 1.7% on the week while ECPG slipped 1.1%, leaving FirstCash's -0.7% weekly performance roughly in line with the group.
The October 22 print will test whether the one-sided options setup is vindicated — and whether the patient short rebuild has identified something the call buyers have not.
See the live data behind this article on ORTEX.
Open FCFS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
